Amicus Therapeutics has opened a new global research facility in Philadelphia, the Cranbury-based biopharmaceutical firm said on Thursday.
The Global Research and Gene Therapy Center of Excellence will be located in uCity Square, a 6.5 million-square-foot, mixed-use community consisting of retail, residential, clinical, office, and laboratory space concentrated around an open-air public square. The center will focus on advancing its portfolio of rare disease gene therapy programs.
“This is a remarkable advancement in the history of Amicus and further strengthens our great collaboration with Dr. Jim Wilson and the Gene Therapy Center at Penn. Philadelphia is a magnet for talent in gene therapy and an engine for innovation. This new global research center located in the ‘cradle of liberty’ will become part of the ‘cradle of cures’ as we move many gene therapy programs forward toward patients in need. With exclusive global rights to 50 rare diseases in collaboration with Dr. Wilson’s team we hope to be able to alleviate an enormous amount of human suffering with the great science work that will be done in this new facility,” John F. Crowley, chairman and CEO of Amicus Therapeutics Inc., said.
The 75,000-square-foot center will take over the top three floors of a new building at 3675 Market St. and be comprised of office and laboratory space. It will ultimately house about 200 researchers focused entirely on gene therapy.
